Latest Conference Articles

BCL-2 Inhibitor Venetoclax Demonstrates Activity in Pretreated AML

Some patients with heavily treated acute myelogenous leukemia benefited from treatment with the BCL-2 inhibitor venetoclax (ABT-199).

Brentuximab Vedotin Combination Shows Promise in Hodgkin Lymphoma

Ninety-six percent of patients with relapsed or refractory Hodgkin lymphoma who received treatment with the combination of brentuximab vedotin and bendamustine responded to treatment without experiencing dose-limiting toxicity.

Ibrutinib Combination Produces High Response Rate in Relapsed/Refractory MCL

Almost 90% of patients with relapsed or refractory mantle cell lymphoma responded to the targeted combination of ibrutinib and rituximab.

Dr. Ian Flinn Discusses Duvelisib Monotherapy in iNHL

Ian Flinn, MD, PhD, director of the hematologic malignancies program at Sarah Cannon Research Institute, discusses findings from a phase I study that explored monotherapy with the PI3K-gamma and delta inhibitor duvelisib (IPI-145) in patients with relapsed/refractory indolent non-Hodgkin lymphoma.

Dr. Jia Ruan Discusses Lenalidomide Plus Rituximab in MCL

Jia Ruan, MD, PhD, is an associate professor at Weill Cornell Medical College, discusses sustained remissions experienced by patients treated with the combination of lenalidomide and rituximab as initial treatment for MCL.

Stem Cell Transplant Feasible, Highly Effective for HIV-Associated Lymphoma

Patients with HIV-associated lymphoma can effectively be treated with autologous hematopoietic stem cell transplantation, with outcomes that are similar to patients without HIV.

Dr. Raje Discusses Anti-CD38 Antibodies in Myeloma

Noopur Raje, MD, from the Multiple Myeloma Program at Massachusetts General Hospital, discusses the unprecedented efficacy seen with monoclonal antibodies as treatments for patients with multiple myeloma.

Elotuzumab Produces Impressive Response Rate in Relapsed/Refractory Multiple Myeloma

Treatment with elotuzumab in combination with lenalidomide and dexamethasone demonstrated encouraging efficacy in patients with relapsed/refractory multiple myeloma.

Nilotinib Shows Efficacy in Phase II Analysis of Elderly Patients With Philadelphia-Positive ALL

Treatment with nilotinib in combination with chemotherapy elicited complete hematological remissions in 87% of elderly patients with newly diagnosed Philadelphia-positive acute lymphoblastic leukemia.

IDH2-Targeting Agent Has Positive Early Results in AML

The novel drug AG-221 generated durable remissions in patients with AML by targeting a mutation of the IDH2 gene in a small, first-in-man study that represents a new, chemotherapy-free approach for attacking the malignancy.

CAR T-Cell Therapy Elicits High Response Rate in Pediatric ALL

The anti-CD19 chimeric antigen receptor-modified T-cell therapy CTL019 demonstrated an impressive 92% complete response rate in pediatric patients with relapsed/refractory acute lymphoblastic leukemia.

Dr. Farhad Ravandi Discusses Vosaroxin in the VALOR Trial

Farhad Ravandi, MD, from the University of Texas MD Anderson Cancer Center in Houston, describes results from the phase III VALOR trial that explored vosaroxin plus cytarabine versus placebo and cytarabine in patients with first relapsed or refractory acute myeloid leukemia.

Frontline Idelalisib Monotherapy Yields High Response Rates in Older Patients With CLL, SLL

Idelalisib monotherapy shows activity in treatment-naïve patients ≥65 years with CLL or SLL, with nearly 90% of patients enrolled in a phase II study demonstrating a partial response.

Dr. Eytan Stein Discusses the IDH2 Inhibitor AG-221 in AML

Eytan Stein, MD, from the Memorial Sloan Kettering Cancer Center, discusses new data from a phase I study exploring the oral IDH2 inhibitor AG-221 in patients with advanced hematologic malignancies, primarily acute myelogenous leukemia and myelodysplastic syndrome.

Brentuximab Vedotin Delivers Unprecedented Post-Transplant PFS Benefit in Relapsed Hodgkin Lymphoma

Patients with relapsed and difficult-to-treat Hodgkin lymphoma who received brentuximab vedotin had an unprecedented 50% higher likelihood of continuing to experience PFS at 2 years.

Anti-CD38 Antibodies Highly Effective in Multiple Myeloma

Two studies spotlighted at the 2014 ASH Annual Meeting characterized the efficacy of treatment with anti-CD38 monoclonal antibodies in the frontline setting and for patients with refractory disease.

Carfilzomib Combination Significantly Increases PFS in Relapsed Multiple Myeloma

Treatment with carfilzomib in combination with lenalidomide and dexamethasone increased PFS by 8.7 months in patients with relapsed multiple myeloma when compared with lenalidomide and dexamethasone alone.

Pembrolizumab Elicits Responses in Classical Hodgkin Lymphoma

Treatment with the PD-1 inhibitor pembrolizumab generated responses in 66% of patients with heavily pretreated classical Hodgkin lymphoma.

Blinatumomab Leads to High MRD Response in B-Precursor ALL

At least 80% of patients with B-precursor acute lymphoblastic leukemia had a complete minimal residual disease response after a single cycle of treatment with the CD19-directed antibody blinatumomab.

Nivolumab Achieves Encouraging Responses in Refractory Classical Hodgkin Lymphoma

In a small phase I trial, most patients with classical Hodgkin lymphoma, having previously failed three or more therapies, responded to the immunotherapy nivolumab.

Dr. Stewart Discusses the Efficacy of Carfilzomib in the ASPIRE Trial

A. Keith Stewart, MBChB, from the Mayo Clinic in Scottsdale, Arizona, discusses findings from the phase III ASPIRE trial that evaluated the novel proteasome inhibitor carfilzomib in combination with lenalidomide and dexamethasone for patients with relapsed multiple myeloma.

Dr. Grupp on Optimal Treatment Settings for CAR-Modified T Cells

Stephan Grupp, MD, PhD, of the Children's Hospital of Philadelphia, discusses the optimal treatment settings for novel CD19-specific CAR-modified T cell therapies in patients with acute lymphoblastic leukemia.

ASH 2014 Preview: Checkpoint Inhibition, CAR Modified T Cells, and Novel Therapies

The top research being presented at the 2014 American Society of Hematology Annual Meeting will focus on immunotherapies and novel agents, according to Marcel R.M. van den Brink, MD, PhD.

Dr. van den Brink Highlights Five Abstracts From ASH 2014

Marcel R.M. van den Brink, MD, PhD, Head, Division of Hematologic Oncology, Memorial Sloan Kettering Cancer Center, provides an overview of five notable studies being presented at the 2014 American Society of Hematology (ASH) Meeting and Exposition.

Dr. Herbst Discusses the State of Immunotherapy in Lung Cancer

Roy S. Herbst, MD, PhD, professor, Yale Cancer Center, chief of medical oncology, Smilow Cancer Hospital at Yale-New Haven, discusses the state of immunotherapy in lung cancer.

Experts Discuss Immunotherapy's Potential in Neuro-Oncology

Immunotherapy's promise as well as its challenges as a treatment for patients with brain cancer was the focus of a plenary session held November 15 at the Society of Neuro-Oncology's (SNO) 2014 Annual Meeting in Miami Beach.

Dr. Raizer Discusses Proton Therapy for Glioma

Jeffrey J. Raizer, MD, Co-Director, Northwestern Brain Tumor Institute, Professor in Neurology, Ken and Ruth Davee Department, Medicine-Hematology/Oncology, Northwestern University Feinberg School of Medicine, discusses a study that analyzed the overall survival and toxicity of proton therapy for large-volume re-irradiation for recurrent glioma.

Oncolytic Virus Shows Early Promise in Glioma

The oncolytic virus Delta-24-RGD can infect, replicate, and kill glioma cells in patients, according to phase I research presented at the 2014 Society for Neuro-Oncology (SNO) Annual Meeting in Miami.

Dr. de Groot Discusses Altiratinib as Potential Treatment for Glioblastoma

John F de Groot, MD, nuro-oncologist, MD Anderson Cancer Center, discusses the efficacy of the novel c-MET inhibitor altiratinib in glioblastoma.

Dr. Stupp Discusses NovoTTF With Temozolomide in Glioblastoma

Roger Stupp, MD, Professor of Oncology, University of Zürich; Chairman, Department of Oncology and Cancer Center, University of Zürich Hospital, Zürich, Switzerland, discusses the interim analysis of the EF-14 trial, which compared NovoTTF-100A together with temozolomide versus temozolomide alone in patients with newly diagnosed glioblastoma multiforme (GBM).